DNTH
Price
$26.50
Change
+$1.84 (+7.46%)
Updated
Sep 5 closing price
Capitalization
852.99M
GMAB
Price
$27.54
Change
+$0.16 (+0.58%)
Updated
Sep 5 closing price
Capitalization
16.82B
60 days until earnings call
Interact to see
Advertisement

DNTH vs GMAB

Header iconDNTH vs GMAB Comparison
Open Charts DNTH vs GMABBanner chart's image
Dianthus Therapeutics
Price$26.50
Change+$1.84 (+7.46%)
Volume$679.67K
Capitalization852.99M
Genmab A/S ADS
Price$27.54
Change+$0.16 (+0.58%)
Volume$2.26M
Capitalization16.82B
DNTH vs GMAB Comparison Chart in %
Loading...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNTH vs. GMAB commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNTH is a Buy and GMAB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (DNTH: $26.50 vs. GMAB: $27.54)
Brand notoriety: DNTH and GMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNTH: 180% vs. GMAB: 179%
Market capitalization -- DNTH: $852.99M vs. GMAB: $16.82B
DNTH [@Biotechnology] is valued at $852.99M. GMAB’s [@Biotechnology] market capitalization is $16.82B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNTH’s FA Score shows that 0 FA rating(s) are green whileGMAB’s FA Score has 0 green FA rating(s).

  • DNTH’s FA Score: 0 green, 5 red.
  • GMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, DNTH is a better buy in the long-term than GMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNTH’s TA Score shows that 5 TA indicator(s) are bullish while GMAB’s TA Score has 5 bullish TA indicator(s).

  • DNTH’s TA Score: 5 bullish, 4 bearish.
  • GMAB’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, DNTH is a better buy in the short-term than GMAB.

Price Growth

DNTH (@Biotechnology) experienced а +12.43% price change this week, while GMAB (@Biotechnology) price change was +10.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

GMAB is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($16.8B) has a higher market cap than DNTH($853M). GMAB has higher P/E ratio than DNTH: GMAB (14.25) vs DNTH (3.24). GMAB YTD gains are higher at: 31.960 vs. DNTH (21.560). GMAB has higher annual earnings (EBITDA): 1.48B vs. DNTH (-129.49M). GMAB has more cash in the bank: 2.9B vs. DNTH (257M). DNTH has less debt than GMAB: DNTH (1.33M) vs GMAB (148M). GMAB has higher revenues than DNTH: GMAB (3.26B) vs DNTH (4.85M).
DNTHGMABDNTH / GMAB
Capitalization853M16.8B5%
EBITDA-129.49M1.48B-9%
Gain YTD21.56031.96067%
P/E Ratio3.2414.2523%
Revenue4.85M3.26B0%
Total Cash257M2.9B9%
Total Debt1.33M148M1%
FUNDAMENTALS RATINGS
DNTH vs GMAB: Fundamental Ratings
DNTH
GMAB
OUTLOOK RATING
1..100
4146
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
58
Fair valued
PROFIT vs RISK RATING
1..100
41100
SMR RATING
1..100
9738
PRICE GROWTH RATING
1..100
4042
P/E GROWTH RATING
1..100
6489
SEASONALITY SCORE
1..100
49n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNTH's Valuation (57) in the null industry is in the same range as GMAB (58). This means that DNTH’s stock grew similarly to GMAB’s over the last 12 months.

DNTH's Profit vs Risk Rating (41) in the null industry is somewhat better than the same rating for GMAB (100). This means that DNTH’s stock grew somewhat faster than GMAB’s over the last 12 months.

GMAB's SMR Rating (38) in the null industry is somewhat better than the same rating for DNTH (97). This means that GMAB’s stock grew somewhat faster than DNTH’s over the last 12 months.

DNTH's Price Growth Rating (40) in the null industry is in the same range as GMAB (42). This means that DNTH’s stock grew similarly to GMAB’s over the last 12 months.

DNTH's P/E Growth Rating (64) in the null industry is in the same range as GMAB (89). This means that DNTH’s stock grew similarly to GMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNTHGMAB
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
71%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
70%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
56%
MACD
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
64%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
61%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
63%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
63%
Declines
ODDS (%)
Bearish Trend about 1 month ago
88%
Bearish Trend 28 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
64%
Aroon
ODDS (%)
N/A
Bullish Trend 4 days ago
48%
View a ticker or compare two or three
Interact to see
Advertisement
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYBIX88.841.49
+1.71%
Rydex Basic Materials Inv
VRSGX29.78N/A
N/A
Virtus KAR Small-Cap Growth R6
ELGAX6.20N/A
N/A
Columbia Select Large Cap Growth A
BPTUX213.15N/A
N/A
Baron Partners R6
ECOIX10.34N/A
N/A
Ecofin Global Renewables Infras Ins

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with IMNM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
+7.46%
IMNM - DNTH
55%
Loosely correlated
+7.35%
OCUL - DNTH
51%
Loosely correlated
+7.09%
XNCR - DNTH
50%
Loosely correlated
+2.15%
CRNX - DNTH
50%
Loosely correlated
+3.97%
ERAS - DNTH
49%
Loosely correlated
+8.78%
More

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with TECH. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then TECH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
+0.58%
TECH - GMAB
38%
Loosely correlated
+2.82%
ARVN - GMAB
37%
Loosely correlated
+2.89%
IPSC - GMAB
37%
Loosely correlated
+5.41%
DNTH - GMAB
35%
Loosely correlated
+7.46%
IMTX - GMAB
35%
Loosely correlated
+9.44%
More